Wedbush Increases Earnings Estimates for Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) – Wedbush boosted their FY2029 earnings per share (EPS) estimates for Ascendis Pharma A/S in a note issued to investors on Wednesday, February 12th. Wedbush analyst Y. Zhong now forecasts that the biotechnology company will post earnings of $14.13 per share for the year, up from their prior forecast of $13.76. Wedbush has a “Outperform” rating and a $181.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64.

A number of other research analysts have also recently issued reports on the company. TD Cowen decreased their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Stifel Nicolaus boosted their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $193.43.

Ascendis Pharma A/S Stock Up 1.1 %

Ascendis Pharma A/S stock opened at $144.08 on Friday. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00. The business’s 50-day moving average price is $132.41 and its two-hundred day moving average price is $132.35. The stock has a market cap of $8.74 billion, a PE ratio of -17.83 and a beta of 0.64.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. T. Rowe Price Investment Management Inc. lifted its stake in Ascendis Pharma A/S by 54.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock valued at $375,226,000 after buying an additional 960,504 shares during the period. Capital International Investors lifted its stake in Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after buying an additional 753,859 shares during the period. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S in the third quarter valued at approximately $60,000. RA Capital Management L.P. lifted its stake in Ascendis Pharma A/S by 4.1% in the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after buying an additional 402,316 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.